SCHEMBL4419660

SCHEMBL4419660

CCOC(=O)CNCCNS(=O)(=O)c1nc(-c2ccccc2)c(C(=O)c2ccccc2)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 8/20 0.53
ALDH1A1 P00352 5/20 0.53
LMNA P02545 4/20 0.53
NPSR1 Q6W5P4 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HTT P42858 2/20 0.53
ADORA2B P29275 2/20 0.53
MAPT P10636 3/20 0.44
RORC P51449 1/20 0.43
RORB Q92753 1/20 0.43
ADORA1 P30542 4/20 0.42
ADORA2A P29274 1/20 0.42
HSD17B10 Q99714 1/20 0.41
DHODH Q02127 1/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4414575 0.87 ALDH1A1 (0.49) ALDH1A1MAPTRORCHSD17B10DHODH
SCHEMBL27657724 0.79 ADORA3 (0.51) ADORA3ALDH1A1LMNANPSR1SMN1; SMN2
SCHEMBL4418662 0.78 LTA4H (0.43) ALDH1A1SMN1; SMN2HSD17B10KDM4EHPGD
SCHEMBL609992 0.77 MAPK1 (0.50) ALDH1A1LMNASMN1; SMN2HTTMAPT
SCHEMBL4418626 0.74 ADORA3 (0.41) ADORA3ALDH1A1LMNANPSR1SMN1; SMN2
SCHEMBL4423896 0.71 KMT2A (0.38) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL4417022 0.70 CA1 (0.39) ALDH1A1MAPTKMT2AHPGD
SCHEMBL31061175 0.70 ADORA3 (1.00) ADORA3ALDH1A1LMNANPSR1SMN1; SMN2
SCHEMBL3136533 0.70 CA2 (0.42) LMNASMN1; SMN2MEN1KMT2AALOX5
SCHEMBL4415280 0.70 ADORA3 (0.56) ADORA3ALDH1A1LMNANPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651642-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-11-04 EP disclosed
US-7211668-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2007-05-01 US disclosed
EP-1651642-A4 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2006-11-29 EP disclosed
EP-1651642-A1 PNA MONOMER AND PRECURSOR Panagene Inc. (KR) 2006-05-03 EP disclosed
US-20050026930-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-02-03 US disclosed
WO-2005009998-A1 PNA MONOMER AND PRECURSOR PANAGENE INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026930-A1 PNA monomer and precursor RNGTT, POLL, NSUN3 ADORA3 127/4885ALDH1A1 3450/4885LMNA 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.